Sanofi Biotechnology;Regeneron Pharmaceuticals, Inc.
发明人:
Corinne Hanotin,Laurence Bessac,Umesh Chaudhari,Robert Pordy,Daniel A. Schwemmer Gipe
申请号：
US16662313
公开号：
US20200255544A1
申请日:
2019.10.24
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and established CHD or CHD risk equivalents that are not adequately controlled by maximum tolerated dose statin therapy.
